<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336913">
  <stage>Registered</stage>
  <submitdate>11/05/2011</submitdate>
  <approvaldate>1/06/2011</approvaldate>
  <actrnumber>ACTRN12611000562976</actrnumber>
  <trial_identification>
    <studytitle>Corticosteroids in Asthma</studytitle>
    <scientifictitle>Randomised, placebo controlled trial investigating adverse effects of Oral Corticosteroids in adults with stable asthma</scientifictitle>
    <utrn>U1111-1121-2419</utrn>
    <trialacronym>CIA</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Asthma</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Asthma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Adults with stable asthma will be randomised to receive a 10 day course of either 1 x Prednisolone 25mg oral capsule twice daily or 1 x placebo oral capsule twice daily and after a 6 week wash out period subjects will begin a 10 day course of the alternate treatment.</interventions>
    <comparator>As this is a cross-over design, all subjects will receive in random order the active drug and the placebo, which is identical in taste and appearance to the prednisolone without containing the active drug, in the form of an oral microcellulose capsule.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Serum Leptin levels</outcome>
      <timepoint>Visit 1 on day 1, visit 2 on day 10, visit 3 on day 52  and visit 4 on day 62.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Subject body weight (kg) to nearest 100g using NU Weigh Log842 scales and weighing in light clothing</outcome>
      <timepoint>Visit 1 on day 1, visit 2 on day 10, visit 3 on day 52 and visit 4 on day 62.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Serum Osteocalcin levels</outcome>
      <timepoint>Visit 1 on day 1, visit 2 on day 10, visit 3 on day 52 and visit 4 on day 62.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Body composition - changes in fat, lean muscle and fluid compartments using whole body scans from dual energy x-ray absoptiometry (DEXA) GE Lunar machine.</outcome>
      <timepoint>visit 2 on day 10 - visit 1 on day 1, visit 4 on day 62 -visit 3 on day 52, visit 4 on day 62 - visit 1 on day 1. (all subjects have the same visits at the same time points regardless of whether they are on the active or alternate treatment, with treatment starting at day 1/visit 1 and ending at day 62/visit 4)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Dietary Intake in kJ measured by 4 day food records and 24hr recalls.  Records will be analysed by Foodworks nutritional analysis software (Xyris). A change in intake of 2000 kJ will be considered significant.</outcome>
      <timepoint>Visit 1 on day 1, visit 2 on day 10, visit 3 on day 52 and visit 4 on day 62.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Adults with stable asthma not currently taking oral corticosteroid medication or other medications known to interact with them. No asthma exacerbation, respiratory tract infection or oral corticosteroids in the previous 4 weeks.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Under 18 years old, diabetes mellitus.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>After a screening visit eligible participants will be randomised by hospital pharmacy to receive either the treatment drug or placebo first. Treatment group allocation will not be revealed to the study investigators.</concealment>
    <sequence>Pharmacy will generate randomisation code using computer generated random numbers.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Pharmacokinetics / pharmacodynamics</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/07/2011</anticipatedstartdate>
    <actualstartdate>1/11/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate>30/04/2013</actualenddate>
    <samplesize>65</samplesize>
    <actualsamplesize>60</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <postcode>2305</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>A/Prof Lisa Wood</primarysponsorname>
    <primarysponsoraddress>Center for Asthma &amp; Respiratory Diseases
Hunter Medical Research Institute
Level 2, West Wing, Lot 1 Kookaburra Circuit
New Lambton Heights, 2305, NSW, Australia</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>University of Newcastle</fundingname>
      <fundingaddress>University Drive, Callaghan, 2308, NSW</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>University of Newcastle</sponsorname>
      <sponsoraddress>University Drive, Callaghan, 2308, NSW</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>There is some evidence to suggest that oral corticosteroid medications may increase appetite and lead to weight gain. However it is unknown whether people with asthma experience these effects when prescribed oral corticosteroids when their asthma symptoms worsen.  This study is designed to examine whether taking oral corticosteroids for a short time affects appetite, dietary intake, body weight or body composition and bone metabolism.</summary>
    <trialwebsite>N/A</trialwebsite>
    <publication>Berthon BS, Gibson PG, McElduff P, et al. Effects of short term oral corticosteroid intake on dietary intake, body weight and body composition in adults with asthma- a randomised controlled trial. Clin Exp Allergy 2015 (epub before print).</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Hunter New England Human Research Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate>25/07/2011</ethicapprovaldate>
      <hrec>11/06/15/3.03</hrec>
      <ethicsubmitdate>13/05/2011</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Lisa Wood</name>
      <address>Center for Asthma &amp; Respiratory Diseases
Hunter Medical Research Institute
Level 2, West Wing, Lot 1 Kookaburra Circuit
New Lambton Heights, 2305, NSW, Australia</address>
      <phone>+61 2 4042 0147</phone>
      <fax>+61 2 4042 0046</fax>
      <email>lisa.wood@newcastle.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Bronwyn Berthon</name>
      <address>The University of Newcastle (UON)
Hunter Medical Research Institute
Level 2, West Wing
C/- University Drive
Callaghan NSW 2308
Australia
</address>
      <phone>+61 2 40420116</phone>
      <fax>+61 2 40420046</fax>
      <email>bronwyn.berthon@newcastle.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Bronwyn Berthon</name>
      <address>The University of Newcastle (UON)
Hunter Medical Research Institute
Level 2, West Wing
C/- University Drive
Callaghan NSW 2308
Australia</address>
      <phone>+ 61 2 40420116</phone>
      <fax>+61 2 40420046</fax>
      <email>bronwyn.berthon@newcastle.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Lisa Wood</name>
      <address>The University of Newcastle (UON)
Hunter Medical Research Institute
Level 2, West Wing
C/- University Drive
Callaghan NSW 2308
Australia
</address>
      <phone>+61240420147</phone>
      <fax />
      <email>lisa.wood@newcastle.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>